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METHODS: A decision analysis model was built based on efﬁcacy measures obtained 
from published clinical trials. Local direct costs were estimated from a payer perspec-
tive using 2009 listed rates of drugs, general ward daily stay and intensive care daily 
stay (with and without mechanical ventilation). The used exchange rate was Col$1968 
per US$ (January 2010). The time horizon was deﬁned as a “censored discharge” (ﬁrst 
to happen among death, discharge or stay until day 35 after therapy ﬁnishing). Effec-
tiveness was measured in terms of clinical cure rates. A multivariate probabilistic 
sensitivity analysis was done through 1000 Monte Carlo simulations. An additional 
model was run including costs associated to the risk of pseudomona transmission. 
These costs were estimated through a Markov model based on the daily probability 
of transmission from an initial pseudomona-free state to contaminated or infected 
states with sensitive and resistant pseudomona strains. RESULTS: Average VAP direct 
costs were US$ 9,912 for imipenem, US$ 10,196 for meropenem and US$ 9,020 for 
doripenem. Costs differences were mainly related to differences in the ICU stay, 
particularly time on mechanical ventilation (13, 13 and 10 days, respectively). Psudo-
mona transmission-related costs were US$ 333; US$ 332 and US$ 191, respectively. 
Monte Carlo analyses showed that doripenem was more cost-effective than merope-
nem and imipenem in 95% and 91% of samples, respectively. Additionally, doripenem 
was dominant over meropenem and imipenem in 46% and 44% of samples, respec-
tively. CONCLUSIONS: Initial treatment of VAP cases with doripenem is the most 
cost-effective alternative compared to other carbapenems as imipenem and merope-
nem. This advantage is related to its effect diminishing the intensive care unit stay due 
to a reduction in time on mechanical ventilation.
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OBJECTIVES: To evaluate the cost-effectiveness of micafungin versus liposomal 
amphotericin B (L-AMB) for ﬁrst-line treatment of invasive candidiasis and candidae-
mia in paediatric patients in the intensive care unit (ICU) setting. METHODS: The 
economic model, designed to simulate a 2-week disease-management period from the 
perspective of the UK National Health Service, used data from a paediatric sub-study 
of a larger, double-blind, randomised trial of micafungin (2 mg/kg) versus L-AMB 
(3 mg/kg). Clinical outcomes included treatment success rates, mortality, treatment 
duration, dosing, discontinuations, and adverse events (AEs). Medical costs included 
acquisition of study drugs, treating drug-related AEs, and hospital length of stays. 
RESULTS: Overall treatment success rates were similar, 73% (35/48) and 76% 
(38/50) in the micafungin and L-AMB arms, respectively; discontinuation rates owing 
to AEs were lower with micafungin, 4% (2/52) compared to 17% (9/54), for L-AMB. 
Average treatment costs were lower (£19,573) in the micafungin versus L-AMB 
(£22,931) groups; the vast majority of these costs were associated with hospitalisation 
(£18,466 and £22,073, respectively), driven by difference in ICU stay. Sensitivity 
analyses showed the results were robustly consistent over a wide range of variables 
but sensitive to length and cost of stay in a paediatric ICU and probability of survival. 
CONCLUSIONS: Micafungin is a cost-effective treatment option compared to L-AMB 
in the management of invasive candidaemia and candidiasis in paediatric patients
PIN17
COST-EFFECTIVE ANALYSIS OF BEHAVIORAL INTERVENTIONS 
UTILIZING MEMS FOR ANTIRETROVIRAL MEDICATION ADHERENCE
Rasu R1, Malewski D1, Thomson N2, Banderas J2, Goggin K2
1University of Missouri Kansas City School of Pharmacy, Kansas City, MO, USA, 2University 
of Missouri Kansas City, Kansas City, MO, USA
OBJECTIVES: This study conducted cost-effective analysis of compliance-enhancing 
behavioral interventions for highly active antiretroviral therapy (HAART) patients. 
Behavioral interventions, especially concerning costs and adherence associated with 
observed therapy and use of medication event monitoring systems (MEMS), are cur-
rently poorly covered in the existing literature. METHODS: Cost-effective analysis of 
Project MOTIV8 (R01MH68197) was conducted on 204 HIV+ patients in Kansas 
City from 2004 to 2008. The study randomized patients into one of three arms: 
control, enhanced counseling (EC), and EC plus observed therapy (OT). This study 
identiﬁed and analyzed time, direct and indirect costs associated with conducting 
randomized clinical trials (RCT) of motivational interviewing-based behavioral inter-
ventions to enhance HAART adherence. Adherence cutoff was set at ≥80% compli-
ance to HAART. The quality adjusted life values were adapted from previous 
literature. TreeAge® Pro2009 was used to create decision trees, cost-effectiveness 
models and sensitivity analysis. ICER and net beneﬁt was calculated based upon a 
willingness to pay of $50,000/QALY. RESULTS: The direct cost was $125,799($616/
patient) and training cost was $9,710($48/patient). The total time cost associated with 
the recruitment effort came to $245,626($1,204/patient) and evaluation of question-
naires and all patient/professional interactions for all 204 patients was $243,632($1194/
patient). Motivational interviewing costs for 134 EC patients came to $271,133($2023/
patient) and $148,570($2321/patient) for 64 OT patients. Total cost per patient: 
Control = $3062, EC = $5085, EC + OT = $7406. ICER found that EC and EC/OT 
were dominated. EC was $38/QALE(month) and EC/OT was $56/QALE(month). Net 
beneﬁt analysis showed that 59% of the patients in EC have to be adherent in order 
to be equivalent. CONCLUSIONS: This study helps to ﬁll in knowledge gaps associ-
ated with behavioral interventions on HIV patients, especially concerning costs and 
adherence associated with observed therapy and use of MEMS. This economic analysis 
can serve as a guide for clinicians and policymakers in determining cost-efﬁcient treat-
ment strategies for patients with HIV.
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OBJECTIVES: We evaluated the cost-effectiveness of a policy of universal inﬂuenza 
vaccination across the US population, compared with the current approach of vaccinat-
ing selected age and risk groups. METHODS: We modeled costs and outcomes of 
seasonal inﬂuenza under a policy of universal vaccination compared with current 
policy, taking a societal perspective. The population was stratiﬁed to model age-speciﬁc 
(<5, 5–17, 18–49, 50–64, and 65+ years) vaccination coverage assumptions, vaccine 
efﬁcacy, and risks of inﬂuenza complications. Probability of inﬂuenza-related illness 
(ILI) and complications, associated health care utilization, direct and indirect costs, and 
survival were estimated for each policy. Model inputs were derived from published 
literature and public sources. No herd effects were considered. For a season’s interven-
tion, ILI cases in that year and lifetime costs and QALYs lost were calculated for each 
policy and used to derive incremental cost-effectiveness ratios for the overall US popu-
lation. One-way and probabilistic sensitivity analyses (PSA) were conducted. RESULTS: 
In base-case analysis, current policy led to 63 million ILI cases per year, resulting in loss 
of 857,000 QALYs and costs of $115 billion (both discounted at 3% annually; costs 
in 2008 USD), while universal vaccination resulted in 61 million cases, 826,000 QALYs 
lost, and $112 billion in costs. Universal vaccination dominated current recommenda-
tion, costing $3 billion less and averting 2 million cases, resulting in 31,000 fewer 
QALYs lost. Results were most sensitive to the percentage of unvaccinated adults 
developing ILI and coverage assumptions with universal policy. PSA indicated consid-
erable uncertainty of results, with universal coverage was dominant in 54%, and domi-
nated in 20%, of iterations. CONCLUSIONS: Our results indicate that a 
recommendation in of universal vaccination in the US is likely to result in lower costs 
and improved outcomes compared with current recommendation, and that this likeli-
hood depends on seasonal attack rates and coverage assumptions.
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OBJECTIVES: Community-acquired intra-abdominal infections are serious conditions 
and expensive events. The purpose of this study was to develop an economic model 
in order to evaluate the cost-effectiveness ratios between ertapenem and the patterns 
of antibiotics used routinely in the treatment of community-acquired intra-abdominal 
infections at the Social Security Mexican Institute (IMSS) from the health care payer’s 
perspective. METHODS: A cost-effectiveness analysis was developed using a Bayesian 
decision-tree model. The model simulates costs and effectiveness outcomes in a 4-week 
period. The comparators were: ertapenem(1 g daily); metronidazole (500 mg every 8 h)/
amikacin (1 g every 12 h); metronidazole (500 mg every 8 h)/cefotaxime (1 g every 8 h); 
metronidazole (500 mg every 8 h)/ciproﬂoxacin (500 mg every 12 h); metronidazole 
(500 mg every 8 h)/ceftriaxone (1 g every 12 h). Resource use and cost data were 
obtained from clinical records (n = 53) of patients being treated at second-level hos-
pitals at IMSS. Effectiveness measures were the percentage of clinical success without 
adverse events (AE) at the end of the follow-up period. Effectiveness data and transi-
tion probabilities were taken from international published literature and were adjusted 
according to the antimicrobial susceptibility identiﬁed locally. The model was cali-
brated according to international pharmacoeconomics guidelines. One-way and 
probabilistic sensitivity analyses were performed using Monte Carlo Simulation sec-
ond-order approach. RESULTS: Patients who received ertapenem experienced 74.4% 
of clinical success without AE, followed by metronidazole/amikacin (52.6%) and 
metronidazole/cefotaxime (40.6%). Mean cost per patient was lower for ertapenem 
(US$6,293.98) followed by metronidazole/amikacin (US$6,830.78) and metronida-
zole/cefotaxime (US$8,511.03). Regarding the ICER’s, ertapenem resulted the domi-
nant therapy. Acceptability curves showed ertapenem as the most cost-effective 
therapy achieving values close to 100% independently of IMSS willingness to pay. 
CONCLUSIONS: The results showed that in México, ertapenem was the most cost-
effective antibiotic therapy for community-acquired intra-abdominal infections. These 
results should be taken into account by Mexican decision makers.
